
News|Articles|July 1, 2003
Pharmaceutical marketing practices and generic drugs in the spotlight
Author(s)Jill Wechsler
Formulary committees, pharmacy benefit managers (PBMs), pharmacists, and physicians face increased scrutiny of their relationships with pharmaceutical manufacturers under a final fraud policy statement from the Office of the Inspector General (OIG) of the Department of Health and Human Services (HHS).
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Researchers Urge Payers to Encourage, not Inhibit, Biosimilar Competition
2
The Rise of AI in Healthcare Shows Both Progress and Roadblocks
3
Challenges & Solutions behind post-acute care models with OneHome's Noel Gilliam
4
Izervay Continued to Show Benefit in Geographic Atrophy in Open-Label Study
5



















































